Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/− bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)
Bendell, J., Hubbard, J., O’Neil, B.H., Jonker, D., Starodub, A., Peyton, J., Pitot, H., Halfdanarson, T., Nadeau, B., Zubkus, J., Adesunloye, B., Edenfield, J., Li, Y.Z., Li, W., Grothey, A., Borodyansky, L., Li, C.J.
Published in Annals of oncology (01.06.2017)
Published in Annals of oncology (01.06.2017)
Get full text
Journal Article
OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation with Consolidation Pembrolizumab in Patients with Unresectable Stage III NSCLC
Durm, G., Althouse, S., Sadiq, A., Jalal, S., Jabbour, S., Zon, R., Kloecker, G., Fisher, W., Reckamp, K., Kio, E., Langdon, R., Adesunloye, B., Gentzler, R., Hanna, N.
Published in Journal of thoracic oncology (01.10.2018)
Published in Journal of thoracic oncology (01.10.2018)
Get full text
Journal Article
P1.18-05 ChemoXRT W/ Consolidation Pembrolizumab in Unresectable Stage III NSCLC: Long-Term Survival Update and Analysis of Post-Progression Therapy
Durm, G., Althouse, S., Sadiq, A., Jalal, S., Jabbour, S., Zon, R., Kloecker, G., Williamson, M., Reckamp, K., Kio, E., Langdon, R., Adesunloye, B., Gentzler, R., Harb, W., Walling, R., Yeon, C., Koczywas, M., Hanna, N.
Published in Journal of thoracic oncology (01.10.2019)
Published in Journal of thoracic oncology (01.10.2019)
Get full text
Journal Article
Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Schneider, B, Miller, KD, Badve, S, O'Neil, B, Helft, P, Chitambar, C, Falkson, C, Nanda, R, McCormick, M, Danso, M, Blaya, M, Langdon, R, Lippman, M, Paplomata, E, Walling, R, Thompson, M, Robin, E, Aggarwal, L, Shalaby, I, Canfield, V, Adesunloye, B, Lee, T, Daily, K, Ma, C, Erban, J, Radhakrishnan, N, Bruetman, D, Graham, M, Reddy, NA, Lynce, FC, Radovich, M
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
LBA-003Phase 1b/II study of cancer stemness inhibitor napabucasin in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts)
Bendell, J, Hubbard, J, O'Neil, B H, Jonker, D, Starodub, A, Peyton, J, Pitot, H, Halfdanarson, T, Nadeau, B, Zubkus, J, Adesunloye, B, Edenfield, J, Li, Y Z, Li, W, Grothey, A, Borodyansky, L, Li, C J
Published in Annals of oncology (01.06.2017)
Get full text
Published in Annals of oncology (01.06.2017)
Journal Article
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Huang, X., Ning, Y. M., Mulquin, M., Madan, R. A., Gulley, J. L., Kluetz, P. G., Adelberg, D., Arlen, P. M., Parnes, H. L., Adesunloye, B., Steinberg, S. M., Wright, J. J., Trepel, J. B., Chen, C., Bassim, C., Apolo, A. B., Figg, W. D., Dahut, W. L.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article